Professor John Griffiths

University of Cambridge

University departments
Cancer Research UK Cambridge Institute

Position: Professor
Personal home page:

PubMed journal articles - click here

Professor John Griffiths is pleased to consider applications from prospective PhD students.

Research description

Magnetic Resonance Imaging and spectroscopy of cancer. Our Group develops and applies Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) methods that will aid in the understanding and therapy of cancer. We use a multimodal MRS and MRI approach in the search for prognostic, diagnostic and therapeutic indices as well as an increased understanding of the underlying tumour biology. We compliment this approach with functional genomics, transcriptomics, proteomics and metabolomics (the latter in the form of a 600MHz NMR instrument). Our MRI/MRS methods, including DCE/MRI for vascular studies, are available for the study of tumour lines and novel drugs and being non-invasive, should allow easy translation to the clinic. We haveseveral clinical projects: (i) the use of pattern recognition techniques to classify brain tumours non-invasively; (ii) MRS studies on ovarian cancer; (iii) 31P MRS for predicting responsiveness of NHLs.

Research Programme
Advanced Cancer Imaging
Keywords

Magnetic Resonance Spectroscopy

jg477
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Chung, Y-L, et al. (2003). Magnetic Resonance Spectroscopic pharmacodynamic markers of Hsp90 inhibitor, 7-allylamino-17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 95: 1624-1633. Pollard, PJ, et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF-1? in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14: 2231-2239 McPhail LD, et al. (2006) Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8: 199-206.